Market Cap | 10.37M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -2.82M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -7.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -45.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -69.00% |
Recommedations | - | Quick Ratio | 0.02 | Shares Outstanding | 55M | 52W Low Chg | 20.00% |
Insider Own | 10.11% | ROA | -272.62% | Shares Float | 48.52M | Beta | 2.03 |
Inst Own | 0.04% | ROE | - | Shares Shorted/Prior | -/- | Price | 0.20 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 25,758 | Target Price | - |
Oper. Margin | - | Earnings Date | Apr 2 | Volume | 3,601 | Change | 7.30% |
Izotropic Corporation, a medical device company, develops and commercializes diagnostic products for detecting breast cancers. It develops and commercializes IzoView, a 360-degree computed tomography imaging system designed for breast imaging. The company was incorporated in 2016 and is headquartered in Surrey, Canada.